Towards Targeted Delivery Systems: Ligand Conjugation Strategies for mRNA Nanoparticle Tumor Vaccines
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
The use of nanoparticles encapsulating messenger RNA (mRNA) as a vaccine has recently attracted much attention because of encouraging results achieved in many nonviral genetic antitumor vaccination studies. Notably, in all of these studies, mRNA nanoparticles are passively targeted to dendritic cells (DCs) through careful selection of vaccination sites. Hence, DC-targeted mRNA nanoparticle vaccines may be an imminent next step forward. In this brief report, we will discuss established conjugation strategies that have been successfully applied to both polymeric and liposomal gene delivery systems. We will also briefly describe promising DC surface receptors amenable for targeting mRNA nanoparticles. Practicable conjugation strategies and receptors reviewed in this paper will provide a convenient reference to facilitate future development of targeted mRNA nanoparticle vaccine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
He, C., Hu, Y., Yin, L., Tang, C., & Yin, C. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.01.065 · Cited by 2,607 · cited 1×
“Targeting ligands can, amongst other functions, help increase the uptake by binding to receptors designed to endocytose larger particles [50],mitigate repulsive forces [51], or improve surface compatibility between the particles and the cellmembrane [49].”
BackgroundFormulation of functionalized PLGA-PEG Nanoparticles for in vivo targeted drug delivery
Cheng, J., Teply, B. A., Sherifi, I., Sung, J., Luther, G., Gu, F. X., Levy-Nissenbaum, E., Radovic-Moreno, A. F., Langer, R., & Farokhzad, O. C. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2006.09.047 · Cited by 1,273
C-type lectin receptors on dendritic cells and langerhans cells
Figdor, C. G., van Kooyk, Y., & Adema, G. J. (2002) · Nature Reviews Immunology · doi:10.1038/nri723 · Cited by 842
Nonviral delivery of self-amplifying RNA vaccines
Geall, A. J., Verma, A., Otten, G. R., Shaw, C. A., Hekele, A., Banerjee, K., Cu, Y., Beard, C. W., Brito, L. A., Krucker, T., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1209367109 · Cited by 741 · cited 1×
“They include the optimization of the mRNAmolecular structure [6, 7], direct in vivo administration of mRNA [8, 9], delivery routes [3, 4], evaluation of rationally designed gene carriers [10–14], and, recently, self-replicating RNA [15].”
BackgroundPolymer vesicles in vivo: correlations with PEG molecular weight
Photos, P. J., Bacakova, L., Discher, B., Bates, F. S., & Discher, D. E. (2003) · Journal of Controlled Release · doi:10.1016/s0168-3659(03)00201-3 · Cited by 527 · cited 1×
“The amount of PEG coverage over a 100 nm liposome needed to prevent aggregation in serum is determined to be >8 mole% (based on total lipid content) in the liposome formulation [44, 45].”
BackgroundA Cationic Nanoemulsion for the Delivery of Next-generation RNA Vaccines
Brito, L. A., Chan, M., Shaw, C. A., Hekele, A., Carsillo, T., Schaefer, M., Archer, J., Seubert, A., Otten, G. R., Beard, C. W., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.133 · Cited by 338 · cited 1×
“They include the optimization of the mRNAmolecular structure [6, 7], direct in vivo administration of mRNA [8, 9], delivery routes [3, 4], evaluation of rationally designed gene carriers [10–14], and, recently, self-replicating RNA [15].”
BackgroundKreiter, S., Selmi, A., Diken, M., Koslowski, M., Britten, C. M., Huber, C., Türeci, Ö., & Sahin, U. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0699 · Cited by 309 · cited 1×
“They include the optimization of the mRNAmolecular structure [6, 7], direct in vivo administration of mRNA [8, 9], delivery routes [3, 4], evaluation of rationally designed gene carriers [10–14], and, recently, self-replicating RNA [15].”
BackgroundIn Vitro and in Vivo mRNA Delivery Using Lipid-Enveloped pH-Responsive Polymer Nanoparticles
Su, X., Fricke, J., Kavanagh, D. G., & Irvine, D. J. (2011) · Molecular Pharmaceutics · doi:10.1021/mp100390w · Cited by 287 · cited 1×
“They include the optimization of the mRNAmolecular structure [6, 7], direct in vivo administration of mRNA [8, 9], delivery routes [3, 4], evaluation of rationally designed gene carriers [10–14], and, recently, self-replicating RNA [15].”
BackgroundKuhn, A. N., Diken, M., Kreiter, S., Selmi, A., Kowalska, J., Jemielity, J., Darzynkiewicz, E., Huber, C., Türeci, Ö., & Sahin, U. (2010) · Gene Therapy · doi:10.1038/gt.2010.52 · Cited by 226
Probst, J., Weide, B., Scheel, B., Pichler, B. J., Hoerr, I., Rammensee, H.-G., & Pascolo, S. (2007) · Gene Therapy · doi:10.1038/sj.gt.3302964 · Cited by 206 · cited 2×
“They include the optimization of the mRNAmolecular structure [6, 7], direct in vivo administration of mRNA [8, 9], delivery routes [3, 4], evaluation of rationally designed gene carriers [10–14], and, recently, self-replicating RNA [15].”
Background
Cited by
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., et al. (2016) · Nature · doi:10.1038/nature18300 · Cited by 1,819
Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
Wang, D.-R., Wu, X.-L., & Sun, Y.-L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01136-2 · Cited by 501
mRNA therapeutics in cancer immunotherapy
Beck, J. D., Reidenbach, D., Salomon, N., Sahin, U., Türeci, Ö., Vormehr, M., & Kranz, L. M. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01348-0 · Cited by 385
Three decades of messenger RNA vaccine development
Verbeke, R., Lentacker, I., De Smedt, S. C., & Dewitte, H. (2019) · Nano Today · doi:10.1016/j.nantod.2019.100766 · Cited by 342
From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases
Pilkington, E. H., Suys, E. J. A., Trevaskis, N. L., Wheatley, A. K., Zukancic, D., Algarni, A., Al-Wassiti, H., Davis, T. P., Pouton, C. W., Kent, S. J., et al. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.06.023 · Cited by 260
Metadata
- Authors
- Phua, K. K. L.
- Venue
- Journal of Immunology Research
- Publisher
- Hindawi Limited
- Published
- 2015
- Volume
- 2015
- Pages
- 1-8
- ISSN
- 2314-7156 (ISSN-L)
- 2314-8861
- OpenAlex
- W2264905794
- Cited by
- 35
- References
- 11
- FWCI
- 1.29
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Towards Targeted Delivery Systems: Ligand Conjugation Strategies for mRNA Nanoparticle Tumor Vaccines. https://app.cochat.ai/papers/10.1155/2015/680620
- The paper
- Phua, K. K. L. (2015). Towards Targeted Delivery Systems: Ligand Conjugation Strategies for mRNA Nanoparticle Tumor Vaccines. Journal of Immunology Research. https://doi.org/10.1155/2015/680620
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.